Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib

Tyrosine kinase inhibitors (TKI) are used for primary therapy in patients with newly diagnosed CML. However, a reliable method for optimal selection of a TKI from the viewpoint of drug sensitivity of CML cells has not been established. We have developed a FRET‐based drug sensitivity test in which a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Takeshi, Fujioka, Mari, Tsuda, Masumi, Murai, Kazunori, Yamaguchi, Kohei, Miyagishima, Takuto, Shindo, Motohiro, Nagashima, Takahiro, Wakasa, Kentaro, Fujimoto, Nozomu, Yamamoto, Satoshi, Yonezumi, Masakatsu, Saito, Souichi, Sato, Shinji, Ogawa, Kazuei, Chou, Takaaki, Watanabe, Reiko, Kato, Yuichi, Takahashi, Shuichiro, Okano, Yoshiaki, Yamamoto, Joji, Ohta, Masatsugu, Iijima, Hiroaki, Oba, Koji, Kishino, Satoshi, Sakamoto, Junichi, Ishida, Yoji, Ohba, Yusuke, Teshima, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029835/
https://www.ncbi.nlm.nih.gov/pubmed/29719934
http://dx.doi.org/10.1111/cas.13625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029835/
https://www.ncbi.nlm.nih.gov/pubmed/29719934
http://dx.doi.org/10.1111/cas.13625

Ejemplares similares